Zacks Investment Research upgraded shares of Biocept, Inc. (NASDAQ:BIOC) from a sell rating to a hold rating in a report issued on Friday.

According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. “

A number of other analysts have also recently weighed in on the company. ValuEngine cut Biocept from a sell rating to a strong sell rating in a research report on Friday, September 1st. Westpark Capital reaffirmed an outperform rating on shares of Biocept in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Biocept currently has an average rating of Hold and a consensus target price of $2.50.

Biocept (NASDAQ BIOC) opened at 1.23 on Friday. The firm has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.44. The firm’s market capitalization is $37.21 million. Biocept has a one year low of $0.74 and a one year high of $3.39.

Biocept (NASDAQ:BIOC) last posted its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Biocept had a negative return on equity of 550.35% and a negative net margin of 359.48%. The company had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.23 million. Equities analysts anticipate that Biocept will post ($0.79) earnings per share for the current year.

WARNING: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at

A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. grew its holdings in Biocept, Inc. (NASDAQ:BIOC) by 9.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 764,351 shares of the medical research company’s stock after buying an additional 66,746 shares during the quarter. Vanguard Group Inc. owned about 2.87% of Biocept worth $1,048,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.92% of the company’s stock.

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Get a free copy of the Zacks research report on Biocept (BIOC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related stocks with our FREE daily email newsletter.